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Background: Hypernatremia is common following traumatic brain injury (TBI) and occurs from a variety of
mechanisms, including hyperosmotic fluids, limitation of free water, or diabetes insipidus. The purpose of this
systematic review was to assess the relationship between hypernatremia and mortality in patients with TBI.
Methods: We searched the following databases up to November 2012: MEDLINE, EMBASE, and CENTRAL. Using a
combination of MeSH and text terms, we developed search filters for the concepts of hypernatremia and TBI and
included studies that met the following criteria: (1) compared hypernatremia to normonatremia, (2) adult patients
with TBI, (3) presented adjusted outcomes for mortality or complications.
Results: Bibliographic and conference search yielded 1,152 citations and 11 abstracts, respectively. Sixty-five articles
were selected for full-text review with 5 being included in our study. All were retrospective cohort studies totaling
5,594 (range 100–4,296) patients. There was marked between-study heterogeneity. The incidence of hypernatremia
ranged between 16% and 40%. Use of hyperosmolar therapy was presented in three studies (range 14-85% of patients).
Hypernatremia was associated with increased mortality across all four studies that presented this outcome. Only one
study considered diabetes insipidus (DI) in their analysis where hypernatremia was associated with increased mortality
in patients who did not receive DDAVP.
Conclusions: Although hypernatremia was associated with increased mortality in the included studies, there was
marked between-study heterogeneity. DI was a potential confounder in several studies. Considering these limitations,
the clinical significance of hypernatremia in TBI is difficult to establish at this stage.
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Each year in the United States, 1.4 million patients suffer a
traumatic brain injury (TBI), of which 235,000 patients are
hospitalized and 50,000 die [1]. More than 40% of survivors
will experience long-term disabilities [2]. Despite advances
in neurocritical care, nearly a third of patients admitted
with a severe TBI die, and less than half have a favorable
neurologic outcome [3-5].
Primary and secondary injuries combine to result in
increased vascular permeability, cerebral edema, and ele-
vated intracranial pressure (ICP) [6-8], which itself is a
consistent predictor of poor outcome in patients with* Correspondence: donald.griesdale@vch.ca
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in any medium, provided the original work is pTBI [9,10]. As such, control of ICP remains a central
tenant in the management of patients with TBI [11].
Hyperosmolar therapy in the form of mannitol or hyper-
tonic saline (HTS) promotes egress of water from brain
interstitium thereby lowering ICP [12]. Mannitol is the
agent of choice for the management of increased ICP in
neurocritically ill patients with significant cerebral
edema [13]. However, concerns over postadministration
intravascular volume depletion and renal failure have led
to the emergence of HTS as a therapeutic option [14].
Clinical studies of patients with TBI have confirmed
the ICP lowering effects of HTS [15-17]. HTS has been
used as both a resuscitative agent with bolus administra-
tion [18], as well as a constant infusion to treat hypona-
tremia or to institute hypernatremia in patients with
TBI. However, there are several concerns with ongoing
infusion targeting hypernatremia with HTS. First, thereis an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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when instituting therapy. Hyperosmolarity from hyper-
natremia works in areas of “normal brain” where the
blood–brain barrier remains intact and can result in in-
creased brain volume in contusional areas [19]. Further-
more, the brain accommodates to HTS-induced
sustained hypernatremia by intracellular idiogenic os-
moles accumulation, which raises brain water content,
restores brain volume, and leads to rebound increased
ICP [12,20]. Despite the use in patients with persistently
elevated ICP [21], authors have questioned the benefits
of hypernatremia in patients with TBI [22]. In this con-
text, we conducted a systematic review to investigate the
association of hypernatremia and mortality in patients
with severe TBI.Methods
This article reports on our systematic review in accord-
ance with the Preferred Reporting of Items for System-
atic reviews and Meta-Analyses (PRISMA) statement
[23].Search strategy
We systematically searched MEDLINE (1966 to Novem-
ber 30, 2012), EMBASE (1977 to November 30, 2012),
and The Cochrane Central Register of Control Trials
(CENTRAL) (1948 to November 30, 2012) for rando-
mised and observational studies of hypernatremia and
mortality in patients with traumatic brain injuries. Stud-
ies in all languages were considered for inclusion. We
hand-searched abstracts of the following conferences
from 2000 to present: American Thoracic Society, Ameri-
can College of Chest physicians, American Association
for the Surgery of Trauma, European Association of
Neurosurgical Societies, Congress of Neurological Sur-
geons, and the International Neurotrauma Symposium.
We hand-searched the bibliographies of included studies
and those of relevant review articles.
Using a combination of exploded Medical Subject
Heading (MeSH) terms and text words, we constructed
search filters for MEDLINE review for the concepts
“TBI” and “hypernatremia.” All terms within a filter were
combined with the Boolean OR operator. The TBI filter
contained the MeSH term craniocerebral trauma and
text words: closed head injury, closed head trauma, trau-
matic brain injury, brain injury, tbi and chi. The hyper-
natremia filter contained the MeSH terms “saline
solution, hypertonic” and hypernatremia and text words:
hypernatremia, hypertonic saline. The TBI and hyperna-
tremia filters were then combined using the Boolean
AND operator. Similar search strategy was employed
for EMBASE. The search strategies are presented in
Additional file 1.Selection criteria, data abstraction, and quality
assessment
Independently and in duplicate, two authors (LK and
DG) screened all articles using the following inclusion
criteria: (1) compared hypernatremia (Na >145 mEq/L)
to normonatremia, (2) included adult patients with TBI,
(3) point estimate and 95% confidence interval for mor-
tality or complications, and (4) described adjustment for
potential confounders.
The following data were abstracted: study design, pa-
tient inclusion and exclusion criteria, admission diagno-
sis, Glasgow Coma Scale (GCS), definition and exposure
to hypernatremia, use of hyperosmolar therapy (manni-
tol or HTS), patients diagnosed with diabetes insipidus
(DI), and unadjusted and adjusted point estimates, and
95% confidence intervals for mortality or complications.
Methodological quality and risk of bias was assessed
using the Newcastle-Ottawa Scale (NOS) [24]. The NOS
is a 9-point scale which evaluates included cohort stud-
ies on selection and comparability of cohorts and the as-
sessment of outcome.
Analytical plan
We had initially planned to present a pooled point esti-
mate for mortality across studies. However, it became
clear that there was marked between study heterogen-
eity, which precluded a meta-analysis.
Results
Systematic search
Bibliographic search yielded a total of 1,152 citations
(Figure 1). We initially excluded 1,099 citations (257 du-
plicate citations and 842 from abstract screening). There
were 11 abstracts identified from conference screening
and one from reference screening. This resulted in 65 ci-
tations for full text review. Sixty abstracts were excluded
(reasons listed in Figure 1), resulting in five studies in-
cluded in our systematic review [25-29].
Study characteristics and quality assessment
Study characteristics are presented in Table 1. Four stud-
ies were retrospective, observational cohorts with total
of 5,594 (range 100–4,296) patients [25-28]. One study
claimed to be a randomised trial but was likely an obser-
vational study as no description of randomization was
provided, exposed and nonexposed groups were unequal,
and a time-to-event analysis was performed to adjust for
baseline risk [29]. Four studies were peer-reviewed full
publications [25-28] and one was published in an ab-
stract format [29]. There was marked between-study het-
erogeneity in terms of patient population, exposure to
hypernatremia, consideration of DI in the analysis, and
regression adjustment. Three studies included only pa-
tients with TBI [27-29], and two studies included





Articles included in systematic review
(n=5)
Excluded (n=60)
• Wrong intervention (n=53)
• No control group (n=6) 
• No outcome of interest (n=1)
Published conference abstracts (n=11)
Identified from reference lists (n=1)
Excluded (n=1099)
• Duplicate citations (n=257)
• Abstract screening (n=842)
Figure 1 Study selection flowchart.
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studies included patients with a GCS ≤8 [26,28,29],
whereas two studies did include patients notwithstand-
ing the severity of the TBI [25,27]. The total scores for
the Newcastle-Ottawa Scale are presented in Table 1
with further details presented in Additional file 2.
Hypernatremia and mortality
Four studies presented mortality data, either as mortality
in the intensive care unit (ICU) [25,27,29] or 14-day
mortality [28]. All studies demonstrated a significant as-
sociation between hypernatremia and mortality. There
were differential thresholds for hypernatremia in the
studies that reported mortality, with two studies using
Na >145 mEq/L [28,29], and two studies using
>150 mEq/L [25,27]. The causes of hypernatremia were
multifactorial and discussed below. Three studies in-
cluded patients with DI [25,27,28], although this was
only considered in the analysis in one [28]. One study
with mortality as an outcome did not report data on dia-
betes insipidous [26,29].
In the study by Aiyagari and colleagues, which in-
cluded both TBI and non TBI patients, hypernatremia
was defined as Na >150 mEq/L with further stratification
based on mild (151–155 mEq/L), moderate (156–
160 mEq/L), or severe (>160 mEq/L) hypernatremia
[25]. They observed a progressive increase in mortality
in the univariate analysis from 59 of 458 (13%) fornormonatremia (Na < 151 mEq) to 15 of 52 (29%) for
mild, 13 of 39 (33%) for moderate, and 29 of 56 (52%)
for severe hypernatremia, respectively. Thirty-four of
339 (10%) patients with hypernatremia received vaso-
pressin (which may indicate DI), but this was not con-
sidered in the analyses. Finally, odds ratio (OR) for the
association of serum sodium >160 mEq/L on ICU mor-
tality adjusted for GCS, age, cerebrovascular disease,
intracranial hemorrhage, and mechanical ventilation
were presented. The adjusted odds ratio (OR) were
stratified based on patients who received mannitol (OR
4.8, 95% confidence interval (CI): 2.4–9.6) and those
who did not (OR 4.4, 95% CI: 1.8–10.6), although no for-
mal test of homogeneity was performed. Similarly, Li
and colleagues also observed an increased risk of ICU
mortality with progressive increase in hypernatremia
[27]. The final multivariable logistic regression model in-
cluded GCS, APACHE II score, and dose of mannitol.
There was a progressive increase in the proportion of
patients who had DI from 6 of 34 (18%) in the mild
hypernatremia group (Na 150–154 mEq/L), to 27 of 66
(41%) in the moderate hypernatremia group (Na 155–
159), to 141 of 167 (84%) of patients in the severe hyper-
natremia group (Na ≥160 mEq/L). However, there was
no consideration of DI in their analysis. Shehata and
colleagues reported hypernatremia (Na >145 mEq/L) in
40 of 100 (40%) patients and an ICU mortality in 36%
with a corresponding hazard ratio (HR) of 3.2 (95%
Table 1 Study characteristics included in systematic review
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fied). Maggiore and colleagues performed a Cox propor-
tional hazards analysis conditioning on days of ICU [28].
Hypernatremia (Na >145 mEq/L) occurred in 176 of
1,103 (16%) patient days. When adjusted for baseline risk
of death and for each other, the use of DDAVP (HR 3.9,
95% CI: 1.4–10.3, P < 0.01), but not hypernatremia
(HR 2.0, 95% CI: 0.81–4.8, P = 0.09), was associated
with increased mortality. Point estimates stratified on
desmopressin use also were presented (P = 0.06 for
homogeneity), which resulted in improved model fit as
assessed by a lower Bayes information criterion (BIC).
Hypernatremia was associated with differential effects
on mortality based on whether DDAVP was used or not.
When DDAVP was used, hypernatremia was not associ-
ated with increased rate of 14-day mortality (HR 0.58,
95% CI: 0.07–3.7, P = 0.57). In contrast, in patients not
exposed to DDAVP, hypernatremia was associated with
increased rate of 14-day mortality (HR 4.2, 95% CI: 1.6-
10.2, P = 0.004). Finally in the 51 (39%) patients in
whom ICP was monitored, there was no association
between hypernatremia and ICP.
Hypernatremia and risk of complications
Only one study presented data on complications from
hypernatremia [26]. This study compared patients who
received a continuous 3% hypertonic saline infusion to
normal saline in neurocritical care patients admitted
for ≥5 days with an admission GCS <9. The authors
observed an association between hypernatremia (Na
>155 mEq/L) and an elevated serum creatinine
>132.6 μmol/L (OR 2.8, 95% CI: 1.3–6.2, P = 0.01).
This was an unadjusted analysis. There was no associ-
ation between hypernatremia and the risk of deep vein
thrombosis or risk of infection.
Discussion
In this systematic review, we observed a consistent asso-
ciation of hypernatremia and mortality in patients with
TBI. However, there also was heterogeneity in patient
populations (case-mix), etiology and severity of hyperna-
tremia, and the presentation of the data precluding a
pooled analysis of data. In all but one study [28], DI
(a known strong confounder) was either not reported or
not considered in the analyses. Finally, one study on the
complications associated with hypernatremia observed
an increased risk of elevated creatinine [26].
Hypernatremia has been associated with increased
mortality in a general ICU population [30,31], and in pa-
tients undergoing cardiac surgery [32]. However, it re-
mains unclear whether the increased risk is attributable
to the underlying medical condition of the patient or to
the hypernatremia itself. This is further complicated in
patients with TBI who have multiple additional reasonsto develop hypernatremia, in particular renal loss of
water (mannitol, DI) or hypertonic sodium gain [20].
Clinicians also may be reluctant to treat hypernatremia
for fear of exacerbating cerebral edema and ICP. These
factors expose a limitation of our systematic review and
the included studies: confounding by indication. This
bias exists when variables associated with outcomes in
the study base also are associated with exposure [33]. In
effect, patients will develop hypernatremia for a variety
of different mechanisms, and some of these may be re-
lated to mortality. The decision to allow or induce
hypernatremia by the treating clinician will be influenced
by underlying patient characteristics. For example, clini-
cians may tolerate or induce progressive increase in
serum sodium if the patients are thought to have in-
creased ICP. Additionally, despite the hypothesized
beneficial effects of reduced ICP from hypernatremia,
any relationship between hypernatremia and ICP is
strongly confounded due to the observational nature of
the included studies. Thus, patients with more severe
TBI who will more likely succumb from their injuries
also may have higher degrees of hypernatremia. Al-
though patients who have higher degrees of hypernatre-
mia are at increased risk of dying, their prognosis is
likely dictated by the underlying severity of illness, rather
than the hypernatremia itself. Despite regression adjust-
ment in the included studies, it would be insufficient to
control for the strong confounding by the underlying se-
verity of illness.
A good example of confounding by indication in the
included studies was the management of patient with
DI. DI is a risk factor for mortality in patients with TBI
[34]. In one of the included study, DDAVP use was inde-
pendently associated with an increased mortality [28].
Given these results, the authors appropriately provided
subgroup point estimates for the association between
hypernatremia and mortality in patients with and with-
out DI (as indicated by DDAVP use). It must be noted
that urine output or laboratory investigations were not
used to support the presumption of DI in the studies.
Despite this weakness, they observed that when DI was
present, hypernatremia provided no additional attribut-
able mortality. In contrast, in patients without DI, in-
creased mortality was observed with hypernatremia.
Two studies in this systematic review included patients
with DI and did not adjust for this in the analyses
[25,27]. Thus, it is likely that the mortality associated
with hypernatremia observed in these studies may be
partially explained by those patients who developed DI.
For example, in the study by Li and colleagues, of the
167 patients who developed a serum sodium ≥160, 145
died (87%) and 141 (84%) had DI [27]. The effect of time
is another strong confounder not addressed by the ma-
jority of studies included in this systematic review. Time
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tionship between serum sodium levels and ICP [35]. Use
of Cox proportional hazards modeling, as used in the
study by Maggiore and colleagues [28], allows for adjust-
ment of time-varying covariates and reduces confound-
ing by time. Finally, the association of hypernatremia
and AKI seen in the study by Froelich and colleagues
likely reflects unmeasured confounding as no adjusted
analysis was presented [26].
There are additional important limitations to our system-
atic review. First, two studies included patients without TBI
[25,26]. Thus, interpolating the overall results of these stud-
ies to the subgroup of patients with TBI is problematic. Sec-
ond, although briefly discussed above, the underlying
etiology for hypernatremia is not known. Hypernatremia
may occur either through sodium gain (HTS) or free water
loss (lack of access to free water, DI, or mannitol) [20,21]. It
may be intentionally induced by the clinician (mannitol or
HTS), tolerated (lack of free water), difficult to treat, or a
combination of all of these. Importantly, the underlying
mechanism and rational may be critical to interpreting the
results of hypernatremia. The purpose of this systematic re-
view was simply to highlight some of these important limi-
tations. Finally, additional important consequences of
induced hypernatremia from mannitol and HTS were not
included: metabolic derangements, volume depletion, and
overload.
There is a central question of great interest to neuroin-
tensivists. Namely, does hyperosmolar therapy by altering
serum sodium concentration improve neurological out-
comes after TBI? There is a clear paradox here that high-
lights a gap in the literature. On one hand, hyperosmolar
therapy from mannitol or HTS has a strong biologic ration-
ale and lowers ICP in randomised studies [12,15-17,36]. On
the other hand, this systematic review raises concerns of
hypernatremia, an endpoint for HTS therapy [21]. Authors
have expressed concerns using HTS given the small size
and nonrandomised nature of the available literature [22].
The dose, duration, and serum sodium target of the inter-
vention remains unclear. Furthermore, HTS and mannitol
have serious adverse effects on their own. Mannitol admin-
istration can lead to renal failure, metabolic derangements
(hypochloremic alkalosis), and rebound increases in ICP.
HTS can lead to volume expansion, heart failure, and
hyperchloremic acidosis [12]. Although further observa-
tional studies may help to delineate a role for hypernatre-
mia for the management of patients with TBI, whether or
not a causality link exists with the use of therapies aiming
to target high levels of natremia will need to be established.
Conclusions
In our systematic review, we observed that hypernatre-
mia in patients with TBI may be associated with in-
creased mortality. However, the overall high risk of biasof included studies, the between-study heterogeneity in
clinical design and analyses, and the remaining con-
founders may explain part of these findings. Further re-
search should explore the impact of targeting lower
versus higher levels of natremia in patients with trau-
matic brain injury.Additional files
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